Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Clinical trial NCT06563895 · RECRUITING

Trial details

NCT number: NCT06563895
Sponsor: Eidos Therapeutics, a BridgeBio company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Amyloidosis Amyloid Cardiomyopathy Transthyretin Amyloidosis Cardiomyopathies Heart Diseases Polyneuropathies

Start date: 2025-05-12
Primary completion: 2031-10-01
Enrollment: 587

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.